Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 11, 2024

Duvelisib Plus Romidepsin for Relapsed/Refractory T-Cell Lymphomas

Nature Medicine


Additional Info

Nature Medicine
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Nat. Med. 2024 Jun 17;[EPub Ahead of Print], SM Horwitz, AJ Nirmal, J Rahman, R Xu, E Drill, N Galasso, N Ganesan, T Davey, H Hancock, L Perez, C Maccaro, A Bahgat, E Marzouk, E Cathcart, A Moskowitz, A Noy, A Kumar, E Jacobsen, DC Fisher, N Mehta-Shah, YH Kim, M Khodadoust, N Kotlov, A Nikitina, O Kudryashova, V Zubareva, K Zornikova, N Shin, M Sorokina, S Degryse, E Postovalova, A Bagaev, K Hosszu, D McAvoy, JJ Boelens, W Wu, Z Ciantra, JW Appelt, C Trevisani, S Amaka, DM Weinstock, SA Vardhana

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading